Target Name: NOTCH2
NCBI ID: G4853
Other Name(s): Neurogenic locus notch homolog protein 2 (isoform 2) | hN2 | Notch2 intracellular domain | Notch receptor 2, transcript variant 1 | Notch homolog 2 | Notch 2 receptor | Notch receptor 2, transcript variant 2 | NOTCH2 variant 1 | AGS2 | NOTCH2 variant 2 | HJCYS | notch 2 | N2ECD | Neurogenic locus notch homolog protein 2 | Notch 2 intracellular domain | neurogenic locus notch homolog protein 2 | notch receptor 2 | NOTC2_HUMAN | N2ICD | Neurogenic locus notch homolog protein 2 (isoform 1) | Notch 2 | NOTCH2 (2ICD)_HUMAN | Notch 2 extracellular truncation

NOTCH2: A Potential Drug Target and Biomarker

Notch2 is a transmembrane protein that plays a crucial role in neural development and plasticity. It is a member of the Notch gene family, which is known for its role in cell-mediated communication and tissue repair. In addition to its role in neural development, NOTCH2 has also been shown to be involved in various physiological processes, including cell survival, angiogenesis, and inflammation.

The NOTCH2 gene was first identified in 1996 and has since been shown to encode a 21-kDa protein that is expressed in various tissues, including brain, spleen, and pancreas. The protein is composed of an N-terminal extracellular domain, a transmembrane segment, and an C-terminal intracellular domain.

Functional studies have shown that NOTCH2 is involved in various cellular processes, including cell adhesion, migration, and survival. It has been shown to play a role in the development and maintenance of neural stem cells, and has been shown to be involved in the regulation of neural cell proliferation and differentiation. In addition, NOTCH2 has also been shown to be involved in the regulation of pain perception and neuroinflammation.

Due to its involvement in various physiological processes, NOTCH2 has been considered as a potential drug target. Several studies have shown that inhibition of NOTCH2 has been shown to have neuroprotective effects, including the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, NOTCH2 has also been shown to be involved in various types of cancer, including melanoma and breast cancer.

A number of potential NOTCH2 antagonists have been identified and are currently being studied as potential drug targets. One of the most promising NOTCH2 antagonists is a small molecule called PF-484656, which is currently being investigated as a potential treatment for various neurological disorders, including Alzheimer's disease.

In addition to its potential as a drug target, NOTCH2 has also been shown to be a potential biomarker. The NOTCH2 protein is expressed in various tissues and has been shown to be involved in the regulation of various physiological processes, including cell adhesion, migration, and survival. In addition, NOTCH2 has been shown to be involved in the regulation of neural stem cell proliferation and differentiation, which could be used as a potential biomarker for the diagnosis and treatment of neural stem cell disorders.

In conclusion, NOTCH2 is a transmembrane protein that is involved in various physiological processes, including neural development and plasticity. Its role in these processes makes it a potential drug target, and its potential as a biomarker makes it an attractive target for the development of new treatments for various neurological disorders. Further research is needed to fully understand the function of NOTCH2 and its potential as a drug and biomarker.

Protein Name: Notch Receptor 2

Functions: Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus (PubMed:21378985, PubMed:21378989). Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation (PubMed:29149593). Positively regulates self-renewal of liver cancer cells (PubMed:25985737)

More Common Targets

NOTCH2NLA | NOTCH2NLC | NOTCH3 | NOTCH4 | NOTO | NOTUM | NOVA1 | NOVA1-DT | NOVA2 | NOX1 | NOX3 | NOX4 | NOX5 | NOXA1 | NOXO1 | NOXRED1 | NPAP1 | NPAP1P2 | NPAP1P9 | NPAS1 | NPAS2 | NPAS3 | NPAS4 | NPAT | NPB | NPBWR1 | NPBWR2 | NPC1 | NPC1L1 | NPC2 | NPCDR1 | NPDC1 | NPEPL1 | NPEPPS | NPEPPSP1 | NPFF | NPFFR1 | NPFFR2 | NPHP1 | NPHP3 | NPHP3-ACAD11 | NPHP3-AS1 | NPHP4 | NPHS1 | NPHS2 | NPIPA1 | NPIPA5 | NPIPA8 | NPIPA9 | NPIPB10P | NPIPB11 | NPIPB12 | NPIPB13 | NPIPB15 | NPIPB1P | NPIPB2 | NPIPB3 | NPIPB4 | NPIPB5 | NPIPB7 | NPIPB8 | NPIPB9 | NPIPP1 | NPL | NPLOC4 | NPM1 | NPM1P13 | NPM1P21 | NPM1P22 | NPM1P25 | NPM1P27 | NPM1P28 | NPM1P35 | NPM1P42 | NPM1P47 | NPM1P48 | NPM2 | NPM3 | NPNT | NPPA | NPPA-AS1 | NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R